CONTEXT: Current epidemiological evidence suggests an association between obesity, hyperinsulinemia, and colorectal cancer risk. Adiponectin is a hormone secreted by the adipose tissue, and serum levels are inversely correlated with obesity and hyperinsulinemia. While there is evidence of an association between circulating adiponectin levels and colorectal cancer risk, no association between genes of the adiponectin pathway and colorectal cancer have been reported to date. OBJECTIVE: To determine the association of 10 haplotype-tagging single-nucleotide polymorphisms (SNPs) of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes with colorectal cancer risk. DESIGN, SETTING, AND PATIENTS: Two case-control studies including patients with a diagnosis of colorectal cancer and controls were recruited between 2000 and 2007. Case-control study 1 included a total of 441 patients with a diagnosis of colorectal cancer and 658 controls; both groups were of Ashkenazi Jewish ancestry and from New York, New York. Case-control study 2 included 199 patients with a diagnosis of colorectal cancer and 199 controls from Chicago, Illinois, matched 1:1 for sex, age, and ethnicity. MAIN OUTCOME MEASURES: ADIPOQ and ADIPOR1 SNP frequency among cases and controls. RESULTS: In study 1, after adjustment for age, sex, and SNPs from the same gene, 3 ADIPOQ SNPs and 1 ADIPOR1 SNP were associated with colorectal cancer risk: rs266729 (adjusted odds ratio [AOR], 0.72; 95% confidence interval [CI], 0.55-0.95) and rs822396 (AOR, 0.37; 95% CI, 0.14-1.00) were associated with decreased risk whereas rs822395 (AOR, 1.76; 95% CI, 1.09-2.84) and rs1342387 (AOR, 1.79; 95% CI, 1.18-2.72) were associated with increased risk. In study 2, after adjustment for age, sex, race, and SNPs from the same gene, the ADIPOQ SNP rs266729 was associated with a decreased colorectal cancer risk of similar magnitude as in study 1 (AOR, 0.52; 95% CI, 0.34-0.78). Combined analysis of both studies shows an association of rs266729 with decreased colorectal cancer risk (AOR, 0.73; 95% CI, 0.53-0.99). CONCLUSION: The SNP rs266729, which tags the 5' flanking region of the ADIPOQ gene, is associated with decreased colorectal cancer risk.
CONTEXT: Current epidemiological evidence suggests an association between obesity, hyperinsulinemia, and colorectal cancer risk. Adiponectin is a hormone secreted by the adipose tissue, and serum levels are inversely correlated with obesity and hyperinsulinemia. While there is evidence of an association between circulating adiponectin levels and colorectal cancer risk, no association between genes of the adiponectin pathway and colorectal cancer have been reported to date. OBJECTIVE: To determine the association of 10 haplotype-tagging single-nucleotide polymorphisms (SNPs) of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes with colorectal cancer risk. DESIGN, SETTING, AND PATIENTS: Two case-control studies including patients with a diagnosis of colorectal cancer and controls were recruited between 2000 and 2007. Case-control study 1 included a total of 441 patients with a diagnosis of colorectal cancer and 658 controls; both groups were of Ashkenazi Jewish ancestry and from New York, New York. Case-control study 2 included 199 patients with a diagnosis of colorectal cancer and 199 controls from Chicago, Illinois, matched 1:1 for sex, age, and ethnicity. MAIN OUTCOME MEASURES: ADIPOQ and ADIPOR1 SNP frequency among cases and controls. RESULTS: In study 1, after adjustment for age, sex, and SNPs from the same gene, 3 ADIPOQ SNPs and 1 ADIPOR1 SNP were associated with colorectal cancer risk: rs266729 (adjusted odds ratio [AOR], 0.72; 95% confidence interval [CI], 0.55-0.95) and rs822396 (AOR, 0.37; 95% CI, 0.14-1.00) were associated with decreased risk whereas rs822395 (AOR, 1.76; 95% CI, 1.09-2.84) and rs1342387 (AOR, 1.79; 95% CI, 1.18-2.72) were associated with increased risk. In study 2, after adjustment for age, sex, race, and SNPs from the same gene, the ADIPOQ SNP rs266729 was associated with a decreased colorectal cancer risk of similar magnitude as in study 1 (AOR, 0.52; 95% CI, 0.34-0.78). Combined analysis of both studies shows an association of rs266729 with decreased colorectal cancer risk (AOR, 0.73; 95% CI, 0.53-0.99). CONCLUSION: The SNP rs266729, which tags the 5' flanking region of the ADIPOQ gene, is associated with decreased colorectal cancer risk.
Authors: E Giovannucci; M N Pollak; E A Platz; W C Willett; M J Stampfer; N Majeed; G A Colditz; F E Speizer; S E Hankinson Journal: Cancer Epidemiol Biomarkers Prev Date: 2000-04 Impact factor: 4.254
Authors: Virginia G Kaklamani; Maureen Sadim; Alex Hsi; Kenneth Offit; Carole Oddoux; Harry Ostrer; Habibul Ahsan; Boris Pasche; Christos Mantzoros Journal: Cancer Res Date: 2008-05-01 Impact factor: 12.701
Authors: Claudia Menzaghi; Tonino Ercolino; Rosa Di Paola; Anders H Berg; James H Warram; Philipp E Scherer; Vincenzo Trischitta; Alessandro Doria Journal: Diabetes Date: 2002-07 Impact factor: 9.461
Authors: Robert J MacInnis; Dallas R English; John L Hopper; Andrew M Haydon; Dorota M Gertig; Graham G Giles Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-04 Impact factor: 4.254
Authors: Maria Pini; Melissa E Gove; Raja Fayad; Robert J Cabay; Giamila Fantuzzi Journal: Am J Physiol Gastrointest Liver Physiol Date: 2008-12-12 Impact factor: 4.052
Authors: Boris Pasche; Kari B Wisinski; Maureen Sadim; Virginia Kaklamani; Michael J Pennison; Qinghua Zeng; Naresh Bellam; Jacquelyn Zimmerman; Nengjun Yi; Kui Zhang; John Baron; Daniel O Stram; M Geoffrey Hayes Journal: J Exp Clin Cancer Res Date: 2010-05-25